The worldwide resurgence of interest in macrolide antibiotics has yielded several semisynthetic derivatives of 14-and 16-membered macrolides which have progressed to clinical trials. The structures and in vitro activities of these compounds were summarized in the preceding minireview (19) . In this second article, the pharmacokinetics, immune modulatory effects, and early clinical experiences of these newer macrolide antibiotics are reviewed.
PHARMACOLOGY OF NEWER MACROLIDES Animal pharmacokinetics. Although some improvements in in vitro antimicrobial activity have been obtained with the newer macrolides, greater oral bioavailability and higher and more persistent levels in serum and tissue also offer opportunities to achieve clinical advantages over erythromycin (Table 1) . Since clinical data are becoming available, only a few illustrative examples of the advantageous pharmacokinetics observed in animal models are mentioned.
The oral bioavailability of roxithromycin was increased to 72% in mice and 85% in rats, compared with less than 10% for erythromycin; levels of roxithromycin in serum and tissue were substantially higher, its elimination half-life was longer, and it was more efficacious against experimental infections in rodents than was erythromycin (10) .
Levels of dirithromycin in serum were lower but more persistent than those of erythromycin in mice, rats, dogs, and rhesus monkeys; and high tissue/plasma concentration ratios were obtained (U. Busch Oral administration of azithromycin to mice, rats, beagle dogs, and cynomolgus monkeys resulted in greater biavailability, higher levels in serum, greater tissue/serum concentration ratios, and longer half-lives than obtained with erythromycin (9, 15) ; the combination of the in vitro and pharmacokinetic improvements of azithromycin was demonstrated by its efficacy against several experimental infections which erythromycin failed to cure (15) .
Better absorption with oral administration and chemical stability of clarithromycin resulted in higher concentrations in serum and lung tissue, a longer serum half-life, and greater efficacy than that of erythromycin in rodent models (12 Clarithromycin was rapidly absorbed, reaching peak concentrations in serum 2 h after dosing regardless of dose size. 
MACROLIDES AND THE IMMUNE SYSTEM
The interaction between antimicrobial agents and the various humoral and cellular components of the immune system is an area of active research. Although most studies have used erythromycin, this new feature is applicable to the newer macrolides as well. Potential cooperation between an antibiotic and the immune system is particularly important in patients with impaired immune function, such as patients with acquired immune deficiency syndrome. Erythromycin and macrolides show excellent penetration of polymorphonuclear leukocytes, macrophages, and lymphocytes (5, 11, 18, 25, 26) . This is particularly important in infections with Legionella spp., Mycobacterium spp., Listeria spp., Brucella spp., Staphylococcus aureus, Toxoplasma spp., and Chlamydia spp., which are known to survive intracellularly. Whether or not this class of antibiotics achieves high concentrations in lysosomes of phagocytic cells is unclear. However, intraphagocytic antimicrobial activity was recently reported for erythromycin and clarithromycin (3) .
The evidence suggests that erythromycin is not inhibitory and may interact favorably with immune system function. As mentioned above, erythromycin achieves significant intracellular concentrations and remains microbiologically active within the cell (4, 5, 23, 30) . Bactericidal oxidative metabolism of the polymorphonuclear leukocyte does not appear to be altered by erythromycin (23, 30) . Intracellular penetration of josamycin into alveolar macrophages of patients treated orally with josamycin was recently reported (24) .
Mandell and Ebson reported that erythromycin potentiates polymorphonuclear leukocyte phagocytosis (L. A. Mandell and M. Ebson, 12th Int. Congr. Chemother., p. 184-185, 1981); however, Naess and Solberg and van Rensburg et al. showed no effect on phagocytosis (21, 30) . Conflicting reports have also been published regarding polymorphonuclear leukocyte chemotaxis. Anderson et al., van Rensburg et al., and Aho and Mannisto published studies which support the enhancement of chemotaxis by erythromycin (2, 4, 30). Nelson et al. reported that chemotaxis was diminished and Naess and Solberg and Forsgren and Schmeling reported no effect (14, 21, 23) .
In 1988, Naess and Solberg reported that erythromycin significantly increased the percentage of membrane receptors on polymorphonuclear leukocytes and lymphocytes; however, it did not increase the proportion of lymphocytes rosetting with erythrocyte-antibody cells and erythrocyteantibody-complement cells (21) . Erythromycin did not affect lymphocyte response to mitogen (21) . In addition, erythromycin did not alter the levels of serum immunoglobulin G, A, or M or complement (total hemolytic complement, C3, C4) (30) .
CLINICAL EXPERIENCE WITH NEWER MACROLIDES
Published clinical trial data involving the newer macrolide antibiotics are limited. Several compounds (clarithromycin, azithromycin, dirithromycin) are under development; however, results of the trials have not yet been published. Renewed interest in older macrolides (spiramycin) has surfaced as well, with further exploration of their antimicrobial properties.
Newer macrolide derivatives are expected to retain the clinical indications of erythromycin, which include upper and lower respiratory tract infections, skin and skin structure infections, and genital tract infections caused by erythromycin-susceptible organisms.
Roxithromycin is the most extensively studied of the newer macrolides. Roxithromycin is well tolerated at a dose of 150 mg twice daily and may have a lower incidence of side effects than erythromycin. Equivalent clinical and microbiologic responses in the treatment of lower respiratory tract infections were shown in comparative studies (8, 17) .
Roxithromycin was also efficacious in the treatment of atypical pneumonia caused by Chlamydia psittaci, diagnosed via complement fixation (6) . Favorable clinical responses were also shown in Mycoplasma pneumonitis (13) , genital infections caused by Chlamydia and Ureaplasma spp. (20) , and skin and skin structure infections (1) .
Dirithromycin is in clinical trials to evaluate safety and efficacy in the treatment of pharyngitis, acute-superimposedon-chronic bronchitis, pneumonia, and skin and skin struc There has been one report of clinical experience with miokamycin in the treatment of respiratory tract infections. Clinical response was reported to be good to excellent in 84 of 86 patients. Pathogens were eradicated in all cases in which a bacterial organism was cultured (27) .
Clarithromycin has been used in the therapy of acute and chronic upper and lower respiratory tract infections, with a symptomatic response rate of 88.5% observed. Sixty-one patients were treated with 200 to 400 mg/day for 7 to 14 days. Preliminary studies also indicated the effectiveness of clarithromycin in the treatment of nongonococcal urethritis and cervicitis of chlamydial and unknown origin. Response rates measured 80 to 91.7% (Kobayashi, 26th ICAAC). The in vitro activity of clarithromycin, although similar to that of erythromycin, appears to be greater against Legionella pneumophila. Whether this difference will be seen clinically has as yet to be determined. SUMMARY Erythromycin and related macrolide antibiotics have recently enjoyed a resurgence of clinical interest. This is a result of activity against organisms which are becoming more prevalent, particularly in immunocompromised hosts and, in addition, better understanding of the unique tissue penetration properties and potential immunomodulating properties of macrolides. Other features of clinical interest possessed by certain of the newer macrolides include the potential for once-daily dosing, resistance to acid degradation in the stomach without enteric coating, and possibly reduced gastrointestinal side effects.
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